POST-TEST

5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which of the following descriptions best characterizes the design of the SERENA-6 clinical trial?**
   a. A Phase II dose-escalation trial of 2 different doses of camizestrant for relapsed/refractory breast cancer with an ESR1 mutation
   b. A Phase III switching trial of camizestrant during first-line treatment for breast cancer with an ESR1 mutation
   c. A Phase III trial evaluating first-line camizestrant versus standard endocrine therapy for ER-positive, HER2-negative advanced breast cancer

2. **In a presentation of patient-reported outcomes from the EMERALD trial, which PRO-CTCAE results were reported with elacestrant?**
   a. Fewer patients reported severe nausea by cycle 6 with elacestrant than with the standard therapy
   b. Fewer patients reported severe vomiting by cycle 6 with elacestrant than with the standard therapy
   c. Both a and b
   d. Neither a nor b

3. **In which patient population are various imlunestrant combination regimens being evaluated in Part C and Part E of the EMBER Phase Ib dose-expansion study?**
   a. Patients with triple-negative breast cancer
   b. Patients with ER-positive, HER2-negative breast cancer
   c. Patients with ER-positive, HER2-positive breast cancer

4. **What was the approximate objective response rate for patients who received imlunestrant/trastuzumab/abemaciclib in the dose-expansion phase of the EMBER study?**
   a. 0%
   b. 25%
   c. 50%

5. **What was the approximate median progression-free survival for patients who received imlunestrant/trastuzumab/abemaciclib in the dose-expansion phase of the EMBER study?**
   a. 2.4 months
   b. 6.7 months
   c. 12.1 months